Division of Endocrinology and Metabolism, Clalit Medical Health Care Services, Kiryat Bialik, Haifa and Western Galilee District, Israel.
Bar-Ilan Faculty of Medicine, Safed, Israel.
Endocrine. 2021 Jul;73(1):65-70. doi: 10.1007/s12020-021-02718-w. Epub 2021 Apr 15.
Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes.
Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i.
29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 ± 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 ± 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 ± 1.1 and 7.0 ± 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 ± 68 ng/mL and the mean GH level (SD) was 0.7 ± 0.5 µg/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i.
The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.
糖尿病（DM）是肢端肥大症患者最常见的合并症之一。钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）是糖尿病管理的重要一类药物。然而，关于此类药物在肢端肥大症合并糖尿病患者中的应用，报告的数据有限。
报告接受 SGLT2i 治疗的肢端肥大症合并糖尿病患者的数据。
共确定了 29 例肢端肥大症合并糖尿病患者。9 例患者接受 SGLT-2i 治疗，其中 5 例为女性，4 例为男性，平均年龄（SD）为 61±12 岁。SGLT2i 的平均（SD）治疗时间为 27.5±7.3 个月。SGLT-2i 起始前后的平均 HbA1c 分别为 8.1±1.1%和 7.0±0.9%。SGLT-2i 起始前 IGF-1 水平（SD）为 177±68ng/ml，GH 水平（SD）为 0.7±0.5μg/L。所有 9 例患者仍在接受 SGLT2i 治疗，均未报告与 SGLT2i 相关的不良反应。
本文首次为我们提供了肢端肥大症合并糖尿病患者使用 SGLT2i 的新数据。
